Centogene_Logo.png
CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board
February 01, 2022 05:30 ET | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
Centogene_Logo.png
CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development
January 20, 2022 06:30 ET | Centogene NV
CENTOGENE and Insilico Medicine will work together to identify, rank, and annotate proteins to identify novel therapeutic targets for NPC using AINPC is a rare genetic disease occurring in...
Centogene_Logo.png
CENTOGENE’s CentoCloud® Set to Revolutionize Rare Disease Diagnostics With Decentralized SaaS Platform for Laboratories Around the World
January 04, 2022 08:00 ET | Centogene NV
The CentoCloud solution is a cloud-based Software as a Service (SaaS) platform that enables laboratories around the world to analyze, interpret, and report genomic variants, and will be able to...
Centogene_Logo.png
CENTOGENE Wins Award in Digital Healthcare Innovation for Artificial Intelligence (AI) Platform Leading Biomarker Discovery
December 23, 2021 08:00 ET | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
Centogene_Logo.png
CENTOGENE Announces CEO to Take Temporary Medical Leave of Absence – Biopharmaceutical Industry Veteran Kim Stratton Appointed as Interim CEO
December 20, 2021 08:30 ET | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
Centogene_Logo.png
CENTOGENE Reports Third Quarter 2021 Financial Results
November 24, 2021 07:35 ET | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
Centogene_Logo.png
CENTOGENE to Announce Third Quarter 2021 Financial Results on November 24, 2021
November 18, 2021 06:30 ET | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
Centogene_Logo.png
CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases
November 04, 2021 06:30 ET | Centogene NV
CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
Centogene_Logo.png
CENTOGENE Enrolls First Patient in Frontotemporal Dementia (FTD) Clinical Study
October 28, 2021 06:30 ET | Centogene NV
FTD is a rapidly progressing neurodegenerative disease; up to 30% of all cases worldwide caused by genetic mutations, including the progranulin gene mutation (FTD-GRN)Study will enroll and genetically...
CENTOGENElogo.jpg
CENTOGENE and Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases
October 06, 2021 08:00 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage Company focused on generating...